{
  "docId": "019de075-3630-758c-9196-25f7a74eb952",
  "docSlug": "7e832f58890c6d5f3f05fff919c18d79",
  "documentTitle": "Sarissa Capital | Activist Presentation Deck | 41 slides",
  "authorId": "sarissa-capital",
  "authorName": "Sarissa Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 41,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "The slide uses a narrative structure to link a specific individual's past regulatory/legal issues to their current role as an independent director.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3630-758c-9196-25f7a74eb952/31",
  "deckHref": "/decks/019de075-3630-758c-9196-25f7a74eb952",
  "deckJsonHref": "/decks/019de075-3630-758c-9196-25f7a74eb952.json",
  "deckAnchorHref": "/decks/019de075-3630-758c-9196-25f7a74eb952#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.725
      },
      "kind": "callout",
      "text": "Shortly after US Senator Charles Grassley wrote to the SEC to investigate the stock sales, Wysenski suddenly retired",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03e30a44-afee-4ca8-9f8a-37c1843d6c42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "list",
      "text": "May 7, 2012, Vertex issued a press release announcing interim clinical trial results that were exaggerated. Wysenski (CCO and EVP at Vertex Pharmaceuticals) on a conference call that day “noted that the number of patients who stood to benefit from the combination treatment under review exceeded 70,000 -- a market that could translate into billions of dollars in potential sales.” Vertex’s stock price rose quickly, from $37.41 a share the day before the announcement, to $58.12 the day of, and mere weeks later was trading at $64.85. Prior to the correction of the data, issued on May 29, 2012, Nancy Wysenski personally sold ~$22 M worth of stock",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0a5b148-4a31-4ecc-974d-31f8b2482014",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Ironically, Alkermes lead independent director Nancy Wysenski was accused in a securities fraud and insider trading suit of overstating clinical trial results and then profiting by selling ~$22 M worth of stock",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a249dcaf-6157-4b98-ae80-db68f66643c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Sources: Bloomberg Law, Grassley.Senate.Gov",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7cf97c7-88b4-4765-aec3-c121f894eed3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "63f0078e-4b3d-48fe-a573-2a1342c6e9cc",
      "evidence": "The slide explicitly details a sequence of events leading to a securities fraud accusation and subsequent retirement.",
      "confidence": 0.95
    }
  ],
  "arcBeats": [
    {
      "to": 37,
      "from": 31,
      "beatId": "5b3b49d1-1736-443d-be8c-e26f8cc17d1c",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "Slides 31-37 present the victory, highlighting the solution and the benefits of Sarissa's nominees",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}